Bellevue Asset Management creates independent Advisory Board
(Thomson Reuters ONE) -
Bellevue Asset Management / Bellevue Asset Management creates independent Advisory Board processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Küsnacht, June 14, 2010
Investment expertise in healthcare sector strengthened
As part of the systematic expansion of its sector and investing expertise,
Bellevue Asset Management has created a Healthcare Advisory Board composed of
highly qualified executives with many years of experience as well as
distinguished scientists. This further strengthens the company's proven
competency in the healthcare sector as well as its already extensive
international network. The objectives here are detecting mega trends and
investment opportunities at a very early stage, systematically identifying
groundbreaking innovations and realistically evaluating their prospects of
success and, ultimately, using this knowledge to make sound and successful
investment decisions.
The creation of an independent Healthcare Advisory Board marks another step
forward in the steadfast implementation of Bellevue Asset Management's strategic
expansion of its asset management business. The company has attracted prominent
executives and experts with excellent credentials and track records to its
international Advisory Board. They are industry representatives with high R&D
competence and who are very familiar with regulatory processes or have decades
of experience in managing international companies. The newly constituted board
chaired by William M. Burns, former CEO of the Pharma Division at Roche, will
focus its attention on trends and investment opportunities in the healthcare
sector.
The board members, internationally recognized experts representing diverse
industrial and academic backgrounds, will advise the investment specialists at
Bellevue Asset Management and support them in the evaluation of consequential
medical and technical innovations in the biotechnology and medical technology
sectors as well as in other areas, including the corresponding investment
possibilities.
"The innovative forces at work in the healthcare sector remain as strong as
ever, which makes the early detection of critical trends and an accurate
assessment of the chances of their successful commercial realization all the
more important. We are looking forward to a fruitful and rewarding
interdisciplinary exchange of knowledge and ideas with the portfolio managers,"
says William M. Burns, Chairman of the Advisory Board. Hans-Peter Diener, CEO of
Bellevue Asset Management, adds: "We are honored to be able to consult such
high-caliber professionals while screening, evaluating and realizing investment
opportunities, for it is only through an active discourse with the best experts
worldwide that specialist knowledge and expertise can be maintained and
developed at internationally competitive levels. This, in turn, enables us to
detect future investment ideas early on and realistically assess their
prospects."
The Healthcare Advisory Board consists of the following experts:
William M. Burns (Chairman)
Board member of Roche Group; ex-CEO Roche Pharma; Board member of Chugai and
member of the Advisory Board of Genentech; Board member of Shire and Crucell
Prof. Dr. Dr. Uwe Bicker
Aventis Foundation trustee; Board member of Sanofi-Aventis; Vice Chairman of
Epigenomics AG; Professor at the Faculty of Clinical Medicine Mannheim,
University of Heidelberg
Prof. Dr. Stefan Catsicas
Co-founder of the Tilocor Life Science biotechnology group; Former Professor at
the School of Medicine in Lausanne and Professor, Vice President and Research
Director at the Swiss Federal Institute of Technology (Lausanne)
Dr. Jürgen Schwiezer
Ex-CEO Roche Diagnostics
Prof. Dr. Thomas Szucs
Chairman of Helsana Group and BB Biotech AG; Director of the Institute of
Pharmaceutical Medicine at the University of Basel
Prof. Dr. Otmar D. Wiestler
Chairman of the Management Board and Scientific Director of the German Cancer
Research Center, Heidelberg
Bellevue Asset Management is one of the leading providers of investment
management services in the healthcare sector, specifically in medical technology
and biotechnology. 14 experts in the fields of biochemistry, molecular biology,
medicine and economics manage approximately CHF 2.2 billion using specialized
sector strategies in the healthcare sector. With an average of 10 years of
professional experience and a network of contacts spanning the globe, they are a
key factor for competitive and sustainable investment success.
Based on its profound healthcare expertise Bellevue Asset Management offers a
comprehensive range of investment vehicles:
Traditional investment vehicles
BB Biotech AG (listed investment company)
BB Biotech (Lux) Fund
BB Medtech (Lux) Fund
BB Healthcare (Lux) Fund
Non-traditional investment vehicles
BB Bioventures
BB Biotech Ventures II - III
BB Alpha Health (long/short equity fund)
For further information:
Bellevue Asset Management AG, Seestrasse 16/P.O. Box, CH-8700 Küsnacht/Zurich
Thomas Egger, Tel. +41 (44) 267 67 09, teg(at)bellevue.ch
Images available here
(http://www.bellevue.ch/cms/bellevue_asset_management/page3508.html)
Bellevue Asset Management
Bellevue Asset Management is an independent and highly specialized asset
management boutique focused on managing equity portfolios for selective sector
and regional strategies as well as institutional portfolios, particularly in the
areas of healthcare, new markets and Swiss/European equities.
[HUG#1423774]
--- End of Message ---
Bellevue Asset Management
Seestrasse 16 / P.O. Box Kusnacht/Zurich Switzerland
Press Release Bellevue Asset Mgt (PDF): http://hugin.info/142988/R/1423774/372552.pdf
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 22394
Anzahl Zeichen: 0
contact information:
Town:
Kusnacht/Zurich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bellevue Asset Management creates independent Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
Bellevue Asset Management (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
